Home - Gastroenterology Advisor
WEBFDA Alert: Gastroenterology Drug Approvals and New Indications. The FDA approved a biosimilar for inflammatory bowel diseases and issued several new indications for nonerosive GERD, UC, and PFIC.
Clinician Insights on How to Manage Semaglutide-Induced …
WEBSep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
What We Know About Semaglutide Adverse Events and …
WEBSep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
Assessment of Antispasmodics Available in North America for the ...
WEBOct 15, 2021 · Data on the use of antispasmodics available in North America for the treatment of chronic abdominal pain in patients with disorders of gut-brain interaction (DGBI) vary dramatically in safety and efficacy, according to a literature review published in The American Journal of Gastroenterology.Overall, data supporting the use of antispasmodics in this patient population are lacking.
Weight Reduction Varies for Patients Receiving Semaglutide, …
WEBSep 25, 2024 · The researchers found that the mean percentage weight change at one year was –5.1 and –2.2 percent with semaglutide and liraglutide, respectively; –3.2 and –5.9 percent for T2D and obesity as treatment indication; and –5.5, –2.8, and –1.8 percent with persistent medication coverage, with 90 to 275 medication coverage days, and ...
Gastroparesis Awareness Month: Updated Guidelines to Treat …
WEBAug 19, 2022 · The American College of Gastroenterology (ACG) released updated clinical guidelines on managing gastroparesis (GP). The new recommendations were published in The American Journal of Gastroenterology.. GP is characterized by delayed gastric emptying (GE) of solid food in the absence of mechanical obstruction.
Tradipitant Relieves Nausea, Other Gastroparesis Symptoms
WEBOct 27, 2022 · Tradipitant is efficacious for relieving nausea and other gastroparesis symptoms. Tradipitant significantly improved nausea and other symptoms in patients with idiopathic and diabetic gastroparesis compared with placebo, according to study results presented at the American College of Gastroenterology (ACG) 2022 Annual Meeting, held from October ...
Novel Drug Tradipitant Effective, Safe for Treatment of Nausea in ...
WEBOct 29, 2021 · Tradipitant appears to be an effective and safe treatment option for gastroparesis symptoms, according to research presented at the American College of Gastroenterology (ACG) 2021 Annual Meeting, held from October 22 to 27, 2021, in Las Vegas, Nevada and virtually.
Gastric Intestinal Metaplasia: 2020 AGA Guidelines
WEBMar 12, 2020 · Gastric cancer (GCa) has a significant impact on worldwide morbidity and mortality as the third-leading cause of cancer death in the world. 1 It has traditionally been associated with poor outcomes and limited treatment options by the time patients clinically present. Helicobacter pylori (HP) is the primary cause of intestinal-type noncardia GCa (located in the antrum, body, incisura, or ...
Controversies in the Diagnosis and Treatment of Gastroparesis
WEBIn an editorial published by the American Journal of Gastroenterology, authors Brian E. Lacy, MD, PhD and David J. Cangemi, MD addressed common misconceptions regarding the diagnosis and treatment of gastroparesis (GP).The prevalence, etiology, and pathogenesis of GP were described, along with diagnostic techniques and prognosis.